Catalog No.
DHJ60601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
Fab-G1-kappa
Clonality
Monoclonal
Target
Platelet glycoprotein VI, GP6, GPVI, Glycoprotein 6
Concentration
1.2mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9HCN6
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ACT-017, CAS: 2101829-58-5
Clone ID
Glenzocimab
Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis, PMID: 33375772
Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation, PMID: 32500636
EMA601 and glenzocimab: two glycoprotein VI inhibitory Fabs with different potency., PMID:40171679
Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs., PMID:40171661
Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage., PMID:39818980
New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis., PMID:39675564
Ischemia/reperfusion injury in acute human and experimental stroke: focus on thrombo-inflammatory mechanisms and treatments., PMID:39582054
Platelet collagen receptors and their role in modulating platelet adhesion patterns and activation on alternatively processed collagen substrates., PMID:39499978
The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice., PMID:39150906
Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial., PMID:38885234
Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer., PMID:38838227
GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease., PMID:38453424
Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial., PMID:38267188
Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy., PMID:37541591
Pharmacological Inhibition of Glycoprotein VI- and Integrin α2β1-Induced Thrombus Formation Modulated by the Collagen Type., PMID:36807826
Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition., PMID:36375047
Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke., PMID:36128904
Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis., PMID:33375772
Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation., PMID:32500636
For research use only. Not for human or drug use.
